The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
This is going to go bonkers, well done to everyone who got in early. Short, Medium & Long term it's a no brainer
hope not mate
building nicely steady to 10p imo has to be the first target and then see
whichever way you look at it MA is looking to get his hands on nearly 3Bn revenues for min 5p bid he has the know how the team to turn Debenhams round that i have no doubt !
think peeps should chill hes just upped his stake why would he do that !
good ole loot out at high noon love it !! so he has until 8th to make offer or be wiped out ? cant see him wanting that an offer will come what price tho ?
4-5 months debt free how many AIM companies can guarantee that.
I for one am not fussed about the past future looks bright 4-5 months minimum double your money no brainer imo GLA
RNS reads well should be back on a few radars at this price
Look forward to the day MMs actually want to make a market here, better than 99 pct of AIM shares approaching debt free and profitability enough cash runaway for 3 years. And wouldn’t surprise me if an offer was made at these levels it’s cheap
Lol.... see you at the £1.50 gap 63 billion tonnes
http://itaconix.com/wp-content/uploads/1806-ITX-Roadshow-Presentation-FINAL.pdf
Investment case
Itaconix raised £3.5m on August 1st placing was only given to eligible institutional investors from UK and US and all directors, one director taking £450-500k
Commercial project pipeline potential estimated by management at approximately $30 million
Strong shareholder register (75-80%) institutional investors/Directors holding
Strong cash balance/Low Mcap (fully funded)
Partnerships with leading industry players such as AkzoNobel, Croda and Solvay valued in $20 billion +
Final agreement with Akzonobel before the end of 2018
Investment case
Itaconix raised £3.5m on August 1st placing was only given to eligible institutional investors from UK and US and all directors, one director taking £450-500k
Commercial project pipeline potential estimated by management at approximately $30 million
Strong shareholder register (75-80%) institutional investors/Directors holding
Strong cash balance/Low Mcap (fully funded)
Partnerships with leading industry players such as AkzoNobel, Croda and Solvay valued in $20 billion +
Final agreement with Akzonobel before the end of 2018
Solvay is an advanced materials and chemical company, committed to developing chemistry that addresses key societal challenges. Solvay innovates and partners with customers in diverse global end markets. Its products are used in planes, cars, batteries, smart and medical devices, as well as in mineral and oil and gas extraction, enhancing efficiency and sustainability. Its lightweighting materials promote cleaner mobility, its formulations optimize the use of resources and its performance chemicals improve air and water quality.
Solvay is headquartered in Brussels with around 26,800 employees in 61 countries. Net sales were €10.1 billion in 2017, with 90% from activities where Solvay ranks among the world’s top 3 leaders, resulting in an EBITDA margin of 22%.
3 - Croda £6.6 Billion MCAP Commercial partner revenue growth in homecare and industrial
Croda International Plc the speciality chemical company that creates high performance ingredients and technologies relied upon by industries and consumers globally
https://www.croda.com/en-gb
ITX (Itaconix)
Mcap £6m
Cash approx £4m
52w highs 24p
52w lows 1.50p
Current shareprice 2.35p
Shares in issue 269m
75-80% With Institutional investors/Directors
20-25% Free Float
WHAT WE DO
Itaconix designs and manufactures high performance, cost effective and sustainable ingredients that are key components of products in the personal care, homecare and industrial sectors.
We are the world leader in developing and producing bio-based polymers from itaconic acid, combining the versatile chemistry of itaconic acid with breakthrough manufacturing economics.
PRODUCTS
HOMECARE & INDUSTRIAL
Itaconix® DSP™
Non-phosphate water conditioning in detergents, agriculture, and industry
Itaconix® CHT™
Excellent low-cost water conditioning for autodish detergents
Itaconix® VELASOFT™
Natural skin conditioner for handwash.
Itaconix® ZINADOR™
Easier-to-use and lower cost odor neutralization with no residues.
Itaconix® XDP™
Superior mineral dispersion from a 100% bio-based polymer
Itaconix® TSI™
Better and bio-based scale inhibition in home care or industrial water treatment.
Itaconix® BIOBIND™
Low VOC binders for paints and coatings
PERSONAL CARE
RevCare™ NE 100S
Bio-based hair styling polymer for use in haircare and mascara.
RevCare™ MC
Bio-based malodour management. Contact the company for further information.
RevCap™ Technology
Formaldehyde free, flexible encapsulation technology for sensitive ingredients.
Currently, we estimate that our product range is addressing global markets with an estimated aggregate turnover of $1.4bn per annum, but as a small growing company we recognise the challenge of effectively accessing these markets in a timely fashion. To address this, Itaconix is actively building collaborative partnerships with leading industry players such as AkzoNobel, Croda and Solvay, with the aim of accelerating market adoption of Itaconix's products. In addition, Itaconix has built a distribution network across 14 countries as a channel to market for the personal care business area.
Signed commercial partnerships and agreements
1 -AkzoNobel €20 Billion MCAP
https://www.akzonobel.com/en
Itaconix and AkzoNobel move from the technical evaluation phase to defining a joint marketing effort for Itaconix bio-based chelates
This latest development follows from the initial announcement in September 2017 that AkzoNobel's Specialty Chemicals business would commence the technical evaluation of Itaconix's bio-based chelates. Although commercial details remain to be finalised, both parties target to complete final agreements before the end of 2018. The goal is to establish a strong multi-year relationship to deliver Itaconix's innovative bio-based chelates to customers worldwide, thereby supporting the development of high performance, sustainable, consumer products using Itaconix technology.
2 - Solvay $12 Billion MCAP - First revenues from Solvay PAP license to sec
ITX (Itaconix)
Mcap £6m
Cash approx £4m
52w highs 24p
52w lows 1.50p
Current shareprice 2.35p
Shares in issue 269m
75-80% With Institutional investors/Directors
20-25% Free Float
WHAT WE DO
Itaconix designs and manufactures high performance, cost effective and sustainable ingredients that are key components of products in the personal care, homecare and industrial sectors.
We are the world leader in developing and producing bio-based polymers from itaconic acid, combining the versatile chemistry of itaconic acid with breakthrough manufacturing economics.
PRODUCTS
HOMECARE & INDUSTRIAL
Itaconix® DSP™
Non-phosphate water conditioning in detergents, agriculture, and industry
Itaconix® CHT™
Excellent low-cost water conditioning for autodish detergents
Itaconix® VELASOFT™
Natural skin conditioner for handwash.
Itaconix® ZINADOR™
Easier-to-use and lower cost odor neutralization with no residues.
Itaconix® XDP™
Superior mineral dispersion from a 100% bio-based polymer
Itaconix® TSI™
Better and bio-based scale inhibition in home care or industrial water treatment.
Itaconix® BIOBIND™
Low VOC binders for paints and coatings
PERSONAL CARE
RevCare™ NE 100S
Bio-based hair styling polymer for use in haircare and mascara.
RevCare™ MC
Bio-based malodour management. Contact the company for further information.
RevCap™ Technology
Formaldehyde free, flexible encapsulation technology for sensitive ingredients.
Currently, we estimate that our product range is addressing global markets with an estimated aggregate turnover of $1.4bn per annum, but as a small growing company we recognise the challenge of effectively accessing these markets in a timely fashion. To address this, Itaconix is actively building collaborative partnerships with leading industry players such as AkzoNobel, Croda and Solvay, with the aim of accelerating market adoption of Itaconix's products. In addition, Itaconix has built a distribution network across 14 countries as a channel to market for the personal care business area.
Signed commercial partnerships and agreements
1 -AkzoNobel €20 Billion MCAP
https://www.akzonobel.com/en
Itaconix and AkzoNobel move from the technical evaluation phase to defining a joint marketing effort for Itaconix bio-based chelates
This latest development follows from the initial announcement in September 2017 that AkzoNobel's Specialty Chemicals business would commence the technical evaluation of Itaconix's bio-based chelates. Although commercial details remain to be finalised, both parties target to complete final agreements before the end of 2018. The goal is to establish a strong multi-year relationship to deliver Itaconix's innovative bio-based chelates to customers worldwide, thereby supporting the development of high performance, sustainable, consumer products using Itaconix technology.
2 - Solvay $12 Billion MCAP - First revenues from Solvay PAP license to sec